Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Children with Down Syndrome (DS) and NCI Standard Risk (SR) Acute Lymphoblastic Leukemia (ALL) Have a Superior Five-Year Event-Free Survival (EFS) When Treated with Escalating Intravenous Methotrexate on the Children's Cancer Group (CCG) Study 1991

Yousif Matloub, MD, Bruce C. Bostrom, MD, Stephen Hunger, MD, Anne Angiolillo, MD, Meenakshi Devidas, PhD, Mei La, Nyla A. Heerema, Ph.D., Naomi Winick, MD, James Nachman, MD, Harland Sather, PhD, William L. Carroll, MD, Paul S Gaynon, MD

Blood (2010) 116 (21): 497.

https://doi.org/10.1182/blood.V116.21.497.497

Published: 2010

Journal Articles

Children with NCI Standard Risk Acute Lymphoblastic Leukemia (ALL) and TEL-AML1 or Favorable Chromosome Trisomies Are Almost Certain to Be Cured with Graduated Intensity Therapy: Results of the CCG - 1991 Study.

Yousif Matloub, MD, Bruce C. Bostrom, MD, Anne L Angiolillo, MD, Meenakshi Devidas, PhD, Nyla A. Heerema, PhD, Julie M. Gastier-Foster, PhD, Stephen P Hunger, MD, Harland Sather, PhD, Stephen Linda, William L. Carroll, MD, James B Nachman, MD, Paul S. Gaynon, MD

Blood (2009) 114 (22): 320.

https://doi.org/10.1182/blood.V114.22.320.320

Published: 2009

Journal Articles

Escalating Dose Intravenous Methotrexate without Leucovorin Rescue during Interim Maintenance Is Superior to Oral Methotrexate for Children with Standard Risk Acute Lymphoblastic Leukemia (SR-ALL): Children’s Oncology Group Study 1991

Yousif Matloub, MD, Bruce C. Bostrom, MD, Stephen P. Hunger, MD, Anne L Angiolillo, MD, Catherine Cole, MD, Blythe Thomson, MD, Meenakshi Devidas, PhD, Nyla A. Heerema, PhD, Mei K La, Patrick J. Buckley, MD, PhD, William L. Carroll, MD, Naomi Winick, MD, Harland Sather, PhD, James B Nachman, MD, Paul S. Gaynon, MD

Blood (2008) 112 (11): 9.

https://doi.org/10.1182/blood.V112.11.9.9

Published: 2008

Journal Articles

Bone Marrow (BM) Minimal Residual Disease (MRD) at End of Induction and Interim Maintenance Is Highly Predictive of Outcome in Children with Standard Risk (SR) Acute Lymphoblastic Leukemia (ALL) Treated on the Children’s Oncology Group Study 1991

Yousif Matloub, MD, Paul S. Gaynon, MD, Somasundaram Jayabose, MD, Bruce C. Bostrom, MD, Stephen P. Hunger, MD, Anne L Angiolillo, MD, Meenakshi Devidas, PhD, Stephen Linda, William L. Carroll, MD, Naomi Winick, MD, Harland Sather, PhD, Sharon R Pine, PhD

Blood (2008) 112 (11): 701.

https://doi.org/10.1182/blood.V112.11.701.701

Published: 2008

Journal Articles

Philadelphia Chromosome Negative (Ph-) Very High Risk (VHR) Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents: The Impact of Intensified Chemotherapy on Early Event Free Survival (EFS) in Children’s Oncology Group (COG) Study AALL0031.

Blood (2008) 112 (11): 911.

https://doi.org/10.1182/blood.V112.11.911.911

Published: 2008

Journal Articles

Improved Early Event Free Survival (EFS) in Children with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) with Intensive Imatinib in Combination with High Dose Chemotherapy: Children’s Oncology Group (COG) Study AALL0031.

Blood (2007) 110 (11): 4.

https://doi.org/10.1182/blood.V110.11.4.4

Published: 2007

Journal Articles

Minimal Toxicity of Imatinib Mesylate in Combination with Intensive Chemotherapy for Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) in Children: A Report of the Children’s Oncology Group (COG) AALL0031 Protocol for Very High Risk ALL.

Kirk R. Schultz, MD, Alexander Aledo, MD, W. Paul Bowman, MD, William Slayton, MD, PhD, Harland Sather, PhD, Cheryl L. Willman, PhD, Julie M. Gastier-Foster, PhD, Nyla A. Heerema, PhD, Andrew J. Carroll, PhD, Michael J. Borowitz, PhD, Naomi Winick, MD, Stephen P. Hunger, MD, PhD, William L. Carroll, MD, PhD

Blood (2006) 108 (11): 283.

https://doi.org/10.1182/blood.V108.11.283.283

Published: 2006

Journal Articles

Increased Infection-Related Mortality for Children with Down Syndrome (DS) in Contemporary Children’s Oncology Group (COG) Acute Lymphoblastic Leukemia (ALL) Clinical Trials.

Kelly W. Maloney, MD, Eric Larsen, MD, Leonard A. Mattano, MD, Alison Friedmann, MD, Meenakshi Devidas, PhD, Harland Sather, PhD, Stephen Hunger, MD, Naomi Winick, MD, William L. Carroll, MD

Blood (2006) 108 (11): 1865.

https://doi.org/10.1182/blood.V108.11.1865.1865

Published: 2006

Journal Articles

Double Delayed Intensification (DDI) Is Equivalent to Single DI (SDI) in Children with National Cancer Institute (NCI) Standard-Risk Acute Lymphoblastic Leukemia (SR-ALL) Treated on Children’s Cancer Group (CCG) Clinical Trial 1991 (CCG-1991).

Yousif Matloub, MD, Anne Angiolillo, MD, Bruce Bostrom, MD, Stephen P. Hunger, MD, James Nachman, MD, Harland Sather, PhD, William L. Carroll, MD, Naomi Winick, MD, Paul S. Gaynon, MD

Blood (2006) 108 (11): 146.

https://doi.org/10.1182/blood.V108.11.146.146

Published: 2006

Journal Articles

CCG 1953: Acute Lymphoblastic Leukemia in Infants: Analysis of Prognostic Factors: A Report from the Children’s Oncology Group.

Joanne M. Hilden, MD, Patricia A. Dinndorf, MD, Sharon O. Meerbaum, Harland Sather, PhD, Doojduen Villaluna, PhD, Nyla A. Heerema, PhD, Ron McGlennen, MD, Franklin O. Smith, MD, William G. Woods, MD, Zoann Dryer, MD, Gregory H. Reaman, MD

Blood (2005) 106 (11): 7.

https://doi.org/10.1182/blood.V106.11.7.7

Published: 2005

Journal Articles

Down Syndrome (DS) Patients with Intermediate Risk (IR) Acute Lymphoblastic Leukemia (ALL): Events and Outcome on Children’s Cancer Group (CCG) 1891 Study.

Janet Franklin, MD, MPH, Staci Larsen, BA, Fred Dorey, PhD, Anna Butturini, MD, Cecelia Fu, MD, Beverly Lange, MD, Harland Sather, PhD, Paul Gaynon, MD

Blood (2004) 104 (11): 1958.

https://doi.org/10.1182/blood.V104.11.1958.1958

Published: 2004

Journal Articles

Biology-Driven Classification of Childhood Acute Lymphoblastic Leukemia: A Combined Analysis of Prognostic Markers from the Pediatric Oncology Group (POG) and Children’s Cancer Group (CCG).

Kirk R. Schultz, MD, Jeanette Pullen, MD, Harland Sather, PhD, Jonathan Shuster, PhD, Michael J. Borowitz, MD, Nyla A. Heerema, PhD, Andrew J. Carroll, PhD, Paul S. Gaynon, MD, Bruce M. Camitta, MD

Blood (2004) 104 (11): 519.

https://doi.org/10.1182/blood.V104.11.519.519

Published: 2004

Journal Articles

Outcome after Relapse among Children with Standard Risk (SR) ALL Treated on CCG-1952.

Suman Malempati, MD, Paul S. Gaynon, MD, Harland Sather, PhD, Mei K. La, MS, Linda C. Stork, MD

Blood (2004) 104 (11): 520.

https://doi.org/10.1182/blood.V104.11.520.520

Published: 2004

Journal Articles

Outcome of Children with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Standard Risk (SR) Features: Results of CCG-1952, CCG-1991 and POG 9404.

Yousif Matloub, MD, B.L. Asselin, Linda C. Stork, MD, Meenakshi Devidas, PhD, Harland Sather, PhD, James Nachman, MD, Bruce Camitta, MD, Paul S. Gaynon, MD

Blood (2004) 104 (11): 680.

https://doi.org/10.1182/blood.V104.11.680.680

Published: 2004

Journal Articles

Obesity and Body Weight Independently Predict Relapse and Survival in Preadolescents and Teenagers with Acute Lymphoblastic Leukemia (ALL). A Retrospective Analysis of Five Children Cancer Group (CCG) Studies.

Anna Butturini, MD, Fred Dorey, PhD, Paul Gaynon, MD, Cecilia Fu, MD, Janet Franklin, MD, Stuart Siegel, MD, Nancy Sacks, RN, Nita Siebel, MD, David Henry, MD, Paul Rogers, MD, Beverly Lange, MD, Harland Sather, PhD, Michael Trigg, MD, Archie Bleyer, MD

Blood (2004) 104 (11): 992.

https://doi.org/10.1182/blood.V104.11.992.992

Published: 2004

NARROW

Children with Down Syndrome (DS) and NCI Standard Risk (SR) Acute Lymphoblastic Leukemia (ALL) Have a Superior Five-Year Event-Free Survival (EFS) When Treated with Escalating Intravenous Methotrexate on the Children's Cancer Group (CCG) Study 1991

Children with NCI Standard Risk Acute Lymphoblastic Leukemia (ALL) and TEL-AML1 or Favorable Chromosome Trisomies Are Almost Certain to Be Cured with Graduated Intensity Therapy: Results of the CCG - 1991 Study.

Escalating Dose Intravenous Methotrexate without Leucovorin Rescue during Interim Maintenance Is Superior to Oral Methotrexate for Children with Standard Risk Acute Lymphoblastic Leukemia (SR-ALL): Children’s Oncology Group Study 1991

Bone Marrow (BM) Minimal Residual Disease (MRD) at End of Induction and Interim Maintenance Is Highly Predictive of Outcome in Children with Standard Risk (SR) Acute Lymphoblastic Leukemia (ALL) Treated on the Children’s Oncology Group Study 1991

Philadelphia Chromosome Negative (Ph-) Very High Risk (VHR) Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents: The Impact of Intensified Chemotherapy on Early Event Free Survival (EFS) in Children’s Oncology Group (COG) Study AALL0031.

Improved Early Event Free Survival (EFS) in Children with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) with Intensive Imatinib in Combination with High Dose Chemotherapy: Children’s Oncology Group (COG) Study AALL0031.

Minimal Toxicity of Imatinib Mesylate in Combination with Intensive Chemotherapy for Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) in Children: A Report of the Children’s Oncology Group (COG) AALL0031 Protocol for Very High Risk ALL.

Increased Infection-Related Mortality for Children with Down Syndrome (DS) in Contemporary Children’s Oncology Group (COG) Acute Lymphoblastic Leukemia (ALL) Clinical Trials.

Double Delayed Intensification (DDI) Is Equivalent to Single DI (SDI) in Children with National Cancer Institute (NCI) Standard-Risk Acute Lymphoblastic Leukemia (SR-ALL) Treated on Children’s Cancer Group (CCG) Clinical Trial 1991 (CCG-1991).

CCG 1953: Acute Lymphoblastic Leukemia in Infants: Analysis of Prognostic Factors: A Report from the Children’s Oncology Group.

Down Syndrome (DS) Patients with Intermediate Risk (IR) Acute Lymphoblastic Leukemia (ALL): Events and Outcome on Children’s Cancer Group (CCG) 1891 Study.

Biology-Driven Classification of Childhood Acute Lymphoblastic Leukemia: A Combined Analysis of Prognostic Markers from the Pediatric Oncology Group (POG) and Children’s Cancer Group (CCG).

Outcome after Relapse among Children with Standard Risk (SR) ALL Treated on CCG-1952.

Outcome of Children with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Standard Risk (SR) Features: Results of CCG-1952, CCG-1991 and POG 9404.

Obesity and Body Weight Independently Predict Relapse and Survival in Preadolescents and Teenagers with Acute Lymphoblastic Leukemia (ALL). A Retrospective Analysis of Five Children Cancer Group (CCG) Studies.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only